June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.
(Reuters) - Shares of Idenix Pharmaceuticals Inc rose as much as 16 percent on Wednesday, after the company reported positive mid-stage trial data of its hepatitis C drug, suggesting it was closer...
We are no longer providing equity research on Idenix Pharmaceuticals IDIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We're leaving our fair value estimate in place after reviewing the results from Idenix Pharmaceuticals ' IDIX three-day dose-escalation study for IDX184 in patients with genotype-1 hepatitis C. Idenix's share price plummeted following
We are maintaining our fair value estimate after reviewing Idenix Pharmaceuticals ' IDIX first-quarter results. Although this marked another quarter in the red for Idenix, the firm was able to increase revenue to
We are maintaining our fair value estimate for Idenix Pharmaceuticals IDIX after the firm announced its decision to out-license its novel HIV treatment, IDX899, to GlaxoSmithKline GSK in order to focus
With fourth-quarter results due out next month, we expect 2008 to mark another year of unprofitability for Idenix IDIX . The company did not announce any additional milestone payments during the fourth quarter, but its pipeline continues to
Although Idenix Pharmaceuticals IDIX narrowed its net loss this quarter, we are maintaining our fair value estimate until we see more positive late-stage clinical
We're putting Idenix Pharmaceuticals IDIX under review while we transfer coverage to a new analyst. We will publish a new analysis shortly.
Idenix Pharmaceuticals IDIX , which recently trimmed down and restructured into a development-stage drug firm, is expecting to speed development of new